CVI Holdings’s Madrigal Pharmaceuticals MDGL Stock Holding History

CVI Holdings’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,500	Closed	-$219K	–	202
2023 Q3	$219K	Buy	+1,500	New	+$282K	0.43%	33

Other funds holding MDGL

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CVI Holdings's MDGL Position: Q4 2023 in Review

CVI Holdings sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2023, closing a stake of 1,500 shares — an estimated $219K sold.

CVI Holdings first reported a position in MDGL in Q3 2023 and held it in 1 quarter. The position peaked at $219K in Q3 2023. 226 funds tracked by Wall St. Rank hold MDGL as of Q4 2023.

CVI Holdings reported no remaining Madrigal Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
CVI Holdings sold 1,500 Madrigal Pharmaceuticals shares in Q4 2023, an estimated $219K.
CVI Holdings first reported a position in Madrigal Pharmaceuticals in Q3 2023 and held it in 1 quarter.
CVI Holdings's Madrigal Pharmaceuticals position peaked at $219K in Q3 2023.
226 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2023.

Based on CVI Holdings's 13F filing for Q4 2023, filed 14 Feb 2024.